LPOXY initiates $28M Series A financing with 5 Horizons Ventures to fund pivotal trial
September 4, 2025 | Startland News Staff
PLATTE CITY, Mo. — Funding to secure the upcoming trial of a Missouri biopharmaceutical company’s solution for preventing a deadly gut infection could prove critical in the fight against a condition that claims 80 U.S. lives daily, said Dr. Larry Sutton.
LPOXY Therapeutics, which is developing a novel non-antibiotic therapy to prevent Clostridioides difficile infections (Cdiff), announced Wednesday it has signed a term sheet with 5Horizons Ventures, a life science venture capital firm focused on innovative healthcare solutions in support of a $28 million Series A financing.
Elevator pitch: LPOXY Therapeutics is transforming infection prevention with a first-in-class oral therapeutic aimed at preventing C. difficile colitis, a CDC-designated urgent public health threat that kills over 80 Americans every day. Our unique approach delivers oxygen directly to the gut, creating an environment hostile to C. difficile bacteria without using antibiotics.
The agreement facilitates the formation of an investment syndicate to fund LPOXY’s registrational STOP-Cdiff (SIDIPREV Trial On Prevention of C. difficile Infections) clinical trial.
“5 Horizons Ventures’ commitment marks a major milestone for LPOXY as we move toward launching our pivotal STOP-Cdiff trial,” said Sutton, CEO and co-founder of LPOXY, one of Startland News’ 10 Kansas City Startups to Watch in 2025. “SIDIPREV represents a novel approach to infection prevention that not only addresses a deadly unmet need but also aligns with hospital economics by reducing costly complications within fixed DRG payments.”
ICYMI: LPOXY Therapeutics punches back at gut infection (and a foe with a billion-year head start)
The upcoming trial is designed under the FDA’s Limited Population Pathway for Antibacterial and Antifungal Drugs guidance and is intended to serve as the registrational study for SIDIPREV™, a therapy that aims to prevent life-threatening Cdiff in high-risk hospitalized patients. C. difficile is categorized by the CDC as an urgent public health threat that kills 80 Americans every day.
SIDIPREV is an orally administered, enteric-coated capsule that releases a metered dose of oxygen into the lower gastrointestinal tract, creating an environment hostile to anaerobic pathogens like C. difficile. Oxygen also suppresses toxin production and has mucosal anti-inflammatory effects.
As planned, STOP-Cdiff is a randomized, placebo-controlled superiority trial that will evaluate the efficacy and safety of SIDIPREV in approximately 500 hospitalized patients at elevated risk for Cdiff due to age and antibiotic exposure. LPOXY aims to launch the trial in Q3 2026 and file for approval in 2029.
“We’re impressed by the LPOXY team, their data, and their clear-eyed strategy for succeeding where many anti-infective programs have struggled,” said Paul Ferguson, partner and CFO of 5 Horizons Ventures. “SIDIPREV avoids the reimbursement and resistance-related hurdles that have plagued traditional antibiotics, making this a rare opportunity to unlock real economic value for patients, hospitals, and investors.”
LPOXY is actively building its investment syndicate and is in discussions with other institutional investors aligned with its late-stage clinical strategy.
2025 Startups to Watch
stats here
Related Posts on Startland News
Kansas legal tech startup’s exit unlocks opportunity to accelerate innovation, founder says
An Overland Park startup developing intuitive websites and marketing solutions for small law firms says its just-announced acquisition by a leading cloud-based legal operations platform is the verdict needed to push its services to mid-market clients and beyond. “Combining the best-in-class websites with practice management software unlocks a unique opportunity to deepen product integration and…
Real-world working: Relaunched initiative will put 500 paid teen interns into KC workplaces
A coalition of funders and employers are teaming up to provide 500 high school students across the Kansas City metro with paid summer professional experiences. “It’s really important that we come together as a community for these types of initiatives to make sure our young people are really connecting the dots and moving onto the…
SafetyCulture acquires safety app for decentralized frontline workers who often go it alone
A global workplace operations company with its U.S. headquarters in Kansas City on Tuesday announced the acquisition of SHEQSY, a cloud-based lone worker safety app — a move meant to address an underinvestment in frontline processes, enablement, and emerging technologies, said Luke Anear. “Frontline workers make up 80 percent of our global workforces,” said Anear,…
Startup embraces ‘digital labor’, creating personalized robots for tedious tasks — beginning with cold calls
Salespeople spend too much time searching for emails, making cold calls and setting up meetings — leaving less energy for comprehensive conversations and closing deals, said Nick Smith. His solution: robots for salespeople or, as he calls them, “Sailebots.” “One day I had a revelation that there could be a tool for these mundane tasks.…